# US 2016/0250194 A1 · Methods of Making and Using Thioxothiazolidine and Rhodanine Derivatives as HIV-1 and JSP-1 Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250194 A1
- Document ID: US20160250194A1
- Status: Published application
- Kind: A1
- Application number: 15/059,018
- Filed: 2016-03-02
- Published: 2016-09-01
- Earliest claimed: 2012-03-23
- Assignees: Southern Methodist University; The Johns Hopkins University
- Applicants: Southern Methodist University; The Johns Hopkins University
- Inventors: Edward R. Biehl; Sukanta Kamila; Ted M. Dawson
- Web page: https://patentgrep.com/patent/US20160250194A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- C07D 277/34: Oxygen atoms
- C07D 277/62: Benzothiazoles
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides methods of making and using 5-(2-(indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one derivatives having HIV-1 or JSP-1 inhibitory activity.

## Claims

### Claim 1

A method of reducing the activity of one or more enzymes comprising the steps of:
contacting the one or more enzymes with a thioxothiazolidin compound having a 5-(2-(indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one skeleton to reduce the activity of the one or more enzymes, wherein the one or more enzymes are HIV-1 or JNK-stimulating phosphatase-1 (JSP-1) enzymes or both.

### Claim 2 (depends on 1)

The method of claim 1, wherein the thioxothiazolidin compound reduces an HIV-1 enzyme activity.

### Claim 3 (depends on 1)

The method of claim 1, wherein the thioxothiazolidin compound inhibits the HIV-1 enzyme.

### Claim 4 (depends on 1)

The method of claim 1, wherein the thioxothiazolidin compound reduces an JNK-stimulating phosphatase-1 (JSP-1) enzyme activity.

### Claim 5 (depends on 1)

The method of claim 1, wherein the thioxothiazolidin compound inhibits an JNK-stimulating phosphatase-1 (JSP-1) enzyme.

### Claim 6 (depends on 1)

The method of claim 1, wherein the thioxothiazolidin compound is a 5-(2-(indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one comprising a 5-substituted 2-(indol-3-yl) and a 3, 4, 5 substituted phenyl.

### Claim 7 (depends on 1)

The method of claim 1, wherein the thioxothiazolidin compound is (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-2-thioxo-3-p-tolylthiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(3,4-dimethylphenyl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-2-thioxo-3-p-tolylthiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(4-methoxyphenyl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-3-(4-methoxyphenyl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one; (Z)-4-(5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-4-oxo-2-thioxothiazolidin-3-yl)benzonitrile; (Z)-4-(5-(2-(1H-indol-3-yl)-2-oxoethylidene)-4-oxo-2-thioxothiazolidin-3-yl)benzonitrile; (Z)-5-(2-(5-chloro-1H-indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(benzo[d]thiazol-6-yl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(benzo[d]thiazol-6-yl)-2-thioxothiazolidin-4-one; (Z)-3-(2-(3-(benzo[d]thiazol-6-yl)-4-oxo-2-thioxothiazolidin-5-ylidene)acetyl)-1H-indole-5-carbonitrile; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(3,5-dibromo-4-hydroxyphenyl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(3,5-dichloro-4-hydroxyphenyl)-2-thioxothiazolidin-4-one; (Z)-3-(3,5-dibromo-4-hydroxyphenyl)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-2-thioxothiazolidin-4-one; or (Z)-3-(3,5-dichloro-4-hydroxyphenyl)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-2-thioxothiazolidin-4-one.

### Claim 8 (depends on 1)

The method of claim 1, wherein the thioxothiazolidin compound has the structure:

### Claim 9

A method of treating a subject having an enzyme disorder comprising the steps of:
providing a subject having an enzyme disorder;
wherein the enzyme disorder is an increase in an enzyme activity of an enzyme selected from a HIV-1 enzyme, a JNK-stimulating phosphatase-1 (JSP-1) enzymes or both;
contacting the enzyme with a thioxothiazolidin compound having a 5-(2-(indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one skeleton to reduce the enzyme activity.

### Claim 10 (depends on 9)

The method of claim 9, wherein the thioxothiazolidin compound reduces an HIV-1 enzyme activity.

### Claim 11 (depends on 9)

The method of claim 9, wherein the thioxothiazolidin compound inhibits the HIV-1 enzyme.

### Claim 12 (depends on 9)

The method of claim 9, wherein the thioxothiazolidin compound reduces the JNK-stimulating phosphatase-1 (JSP-1) enzyme activity.

### Claim 13 (depends on 9)

The method of claim 9, wherein the thioxothiazolidin compound inhibits the JNK-stimulating phosphatase-1 (JSP-1) enzyme.

### Claim 14 (depends on 9)

The method of claim 9, wherein the thioxothiazolidin compound is a 5-(2-(indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one comprising a 5-substituted 2-(indol-3-yl) and a 3, 4, 5 substituted phenyl.

### Claim 15 (depends on 9)

The method of claim 9, wherein the thioxothiazolidin compound is (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-2-thioxo-3-p-tolylthiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(3,4-dimethylphenyl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-2-thioxo-3-p-tolylthiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(4-methoxyphenyl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-3-(4-methoxyphenyl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one; (Z)-4-(5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-4-oxo-2-thioxothiazolidin-3-yl)benzonitrile; (Z)-4-(5-(2-(1H-indol-3-yl)-2-oxoethylidene)-4-oxo-2-thioxothiazolidin-3-yl)benzonitrile; (Z)-5-(2-(5-chloro-1H-indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(benzo[d]thiazol-6-yl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(benzo[d]thiazol-6-yl)-2-thioxothiazolidin-4-one; (Z)-3-(2-(3-(benzo[d]thiazol-6-yl)-4-oxo-2-thioxothiazolidin-5-ylidene)acetyl)-1H-indole-5-carbonitrile; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(3,5-dibromo-4-hydroxyphenyl)-2-thioxothiazolidin-4-one; (Z)-5-(2-(1H-indol-3-yl)-2-oxoethylidene)-3-(3,5-dichloro-4-hydroxyphenyl)-2-thioxothiazolidin-4-one; (Z)-3-(3,5-dibromo-4-hydroxyphenyl)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-2-thioxothiazolidin-4-one; or (Z)-3-(3,5-dichloro-4-hydroxyphenyl)-5-(2-(5-methoxy-1H-indol-3-yl)-2-oxoethylidene)-2-thioxothiazolidin-4-one.

### Claim 16 (depends on 9)

The method of claim 9, wherein the thioxothiazolidin compound has the structure:
